Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study

Eculizumab, a humanized monoclonal antibody targeting the C5 complement protein, has been approved for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). The aim of this study is to evaluate the long-term effect...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in neurology Vol. 14; p. 1303874
Main Authors:	Marignier, Romain, Laplaud, David, Zéphir, Hélène, Papeix, Caroline, Leray, Emmanuelle, Amri, Ekbel, Piotaix, Mickaël, de Sèze, Jérôme
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media 22-01-2024 Frontiers Media S.A
Subjects:	complement inhibition disease-modifying therapy eculizumab Human health and pathology Immunology Immunotherapy Life Sciences Neurobiology Neurology neuromyelitis optica spectrum disorders Neurons and Cognition real-world evidence Santé publique et épidémiologie Sensory Organs eculizumab real-world evidence complement inhibition neuromyelitis optica spectrum disorders disease-modifying therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!